BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 17098432)

  • 1. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK).
    Uckun FM; Dibirdik I; Qazi S; Vassilev A; Ma H; Mao C; Benyumov A; Emami KH
    Bioorg Med Chem; 2007 Jan; 15(2):800-14. PubMed ID: 17098432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LFM-A13, a potent inhibitor of polo-like kinase, inhibits breast carcinogenesis by suppressing proliferation activity and inducing apoptosis in breast tumors of mice.
    Sahin K; Tuzcu M; Yabas M; Orhan C; Sahin N; Ozercan IH
    Invest New Drugs; 2018 Jun; 36(3):388-395. PubMed ID: 29139009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemosensitizing anti-cancer activity of LFM-A13, a leflunomide metabolite analog targeting polo-like kinases.
    Uckun FM
    Cell Cycle; 2007 Dec; 6(24):3021-6. PubMed ID: 18073537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo chemosensitizing activity of LFM-A13, a dual-function inhibitor of Bruton's tyrosine kinase and polo-like kinases, against human leukemic B-cell precursors.
    Uckun F; Dibirdik I; Sarkissian A; Qazi S
    Arzneimittelforschung; 2011; 61(4):252-9. PubMed ID: 21650085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase.
    Uckun FM; Zheng Y; Cetkovic-Cvrlje M; Vassilev A; Lisowski E; Waurzyniak B; Chen H; Carpenter R; Chen CL
    Clin Cancer Res; 2002 May; 8(5):1224-33. PubMed ID: 12006542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity.
    van den Akker E; van Dijk TB; Schmidt U; Felida L; Beug H; Löwenberg B; von Lindern M
    Biol Chem; 2004 May; 385(5):409-13. PubMed ID: 15196000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide].
    Mahajan S; Ghosh S; Sudbeck EA; Zheng Y; Downs S; Hupke M; Uckun FM
    J Biol Chem; 1999 Apr; 274(14):9587-99. PubMed ID: 10092645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical toxicity and pharmacokinetics of the Bruton's tyrosine kinase-targeting anti-leukemic drug candidate, alpha-cyano-beta-hydroxy-beta-methyl-N- (2,5-dibromophenyl) propenamide (LFM-A13).
    Uckun FM; Tibbles H; Venkatachalam T; DuMez D; Erbeck D
    Arzneimittelforschung; 2007; 57(1):31-46. PubMed ID: 17341007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo toxicity and antithrombotic profile of the oral formulation of the antileukemic agent, LFM-A13-F.
    Tibbles HE; Samuel P; Erbeck D; Mahajan S; Uckun FM
    Arzneimittelforschung; 2004; 54(6):330-9. PubMed ID: 15281619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic approach to evaluate specificity of small molecule drug candidates inhibiting PLK1 using zebrafish.
    Zhong H; Xin S; Zhao Y; Lu J; Li S; Gong J; Yang Z; Lin S
    Mol Biosyst; 2010 Aug; 6(8):1463-8. PubMed ID: 20625580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation model.
    Cetkovic-Cvrlje M; Uckun FM
    Br J Haematol; 2004 Sep; 126(6):821-7. PubMed ID: 15352986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Large-scale synthesis of GMP grade alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13), a new anti-cancer drug candidate.
    DuMez D; Venkatachalam TK; Uckun FM
    Arzneimittelforschung; 2007; 57(3):155-63. PubMed ID: 17469650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The anti-leukemic Bruton's tyrosine kinase inhibitor alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13) prevents fatal thromboembolism.
    Uckun FM; Vassilev A; Bartell S; Zheng Y; Mahajan S; Tibbles HE
    Leuk Lymphoma; 2003 Sep; 44(9):1569-77. PubMed ID: 14565661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of thiophene inhibitors of polo-like kinase.
    Emmitte KA; Andrews CW; Badiang JG; Davis-Ward RG; Dickson HD; Drewry DH; Emerson HK; Epperly AH; Hassler DF; Knick VB; Kuntz KW; Lansing TJ; Linn JA; Mook RA; Nailor KE; Salovich JM; Spehar GM; Cheung M
    Bioorg Med Chem Lett; 2009 Feb; 19(3):1018-21. PubMed ID: 19097784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity.
    Rudolph D; Steegmaier M; Hoffmann M; Grauert M; Baum A; Quant J; Haslinger C; Garin-Chesa P; Adolf GR
    Clin Cancer Res; 2009 May; 15(9):3094-102. PubMed ID: 19383823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous use of erythropoietin and LFM-A13 as a new therapeutic approach for colorectal cancer.
    Tankiewicz-Kwedlo A; Hermanowicz JM; Domaniewski T; Pawlak K; Rusak M; Pryczynicz A; Surazynski A; Kaminski T; Kazberuk A; Pawlak D
    Br J Pharmacol; 2018 Mar; 175(5):743-762. PubMed ID: 29160911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.
    Steegmaier M; Hoffmann M; Baum A; Lénárt P; Petronczki M; Krssák M; Gürtler U; Garin-Chesa P; Lieb S; Quant J; Grauert M; Adolf GR; Kraut N; Peters JM; Rettig WJ
    Curr Biol; 2007 Feb; 17(4):316-22. PubMed ID: 17291758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha-cyano-beta-hydroxy-beta-methyl-N-[4-(trifluoromethoxy)phenyl] propenamide: an inhibitor of the epidermal growth factor receptor tyrosine kinase with potent cytotoxic activity against breast cancer cells.
    Ghosh S; Zheng Y; Jun X; Narla RK; Mahajan S; Navara C; Mao C; Sudbeck EA; Uckun FM
    Clin Cancer Res; 1998 Nov; 4(11):2657-68. PubMed ID: 9829728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent in vivo anti-breast cancer activity of IN-2001, a novel inhibitor of histone deacetylase, in MMTV/c-Neu mice.
    Joung KE; Min KN; An JY; Kim DK; Kong G; Sheen YY
    Cancer Res; 2006 May; 66(10):5394-402. PubMed ID: 16707467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
    Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
    Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.